Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.69), $0.06 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.